22 results
Primary objectives:1) To evaluate the safety of four different CHMI-trans protocols in healthy malaria-naïve volunteers challenged with Plasmodium falciparum by sporozoite challenge. 2) To determine the best CHMI-trans protocol for induction of…
The primary objective is to determine the safety and tolerability BCG vaccination followed by controlled human malaria infection; and to determine the protective efficacy BCG vaccination against a controlled human malaria infection.
Primary objectives:1) To evaluate the safety of CHMI-trans protocols in healthy malaria-naïve volunteers challenged with Plasmodium falciparum by sporozoite challenge and blood stage challenge. 2) To assess gametocyte infectiousness for Anopheles…
Primary Objective: To determine the safety and tolerability of NF135.C10 sporozoite immunization under chemoprophylaxisSecondary Objectives:• To determine the dose-dependent protective efficacy of NF135.C10 CPS-immunization against homologous…
Primary objective: To delineate the antibody repertoire directed against the pre-erythrocytic stages of Plasmodium falciparum induced by CPS-immunization.Secondary objectives: • To assess the functionality of CPS-immunization induced antibodies.• To…
Primary objective: To determine whether CPS-immunization with NF54 Plasmodium falciparum parasites provides protection against challenge with the genetically distinct P. falciparum clones, NF135.C10 or NF166.C8.Secondary objectives:• To investigate…
Primary Objective: To assess the proportion of volunteers who develop parasitemia after Controlled Human Malaria Infection with bites from one, two or five NF166.C8- or NF135.C10-infected mosquitoes.Secondary Objectives: To assess kinetics of…
Primary objective: To investigate whether CPS immunization confers protection to a blood stage challenge.Secondary objectives: • To study and compare parasitemia after challenge between study groups• To analyze and compare the immune responses…
Primary Objective: To determine if two thirds or one third of the CPS immunization dose still induces complete protection against an experimental malaria challenge. Secondary Objectives: • To study and compare parasitemia and kinetics of parasitemia…
• Primary objective: To achieve a 100% infection rate of human volunteers by intradermal injection of aseptic, purified, cryopreserved Pf sporozoites (PfSPZ Challenge). • Secondary objective: To compare parasite kinetics between different doses of…
• Primary objective (parasitological): To investigate the kinetics of parasitemia of different Plasmodium falciparum isolates• Secondary objective (immunological): To investigate parasite development and immunological properties of different…
Primary Objective: To compare protection against controlled Plasmodium falciparum malaria infection after immunization with sporozoites under chloroquine with immunization under mefloquine prophylaxis. Secondary Objectives: • To study and compare…
Primary objective (parasitological): To investigate the parasitaemic kinetics of three different Plasmodium falciparum isolates (NF54, NF135 and NF166) during a controlled human malaria infection.Secondary objective (parasitological, clinical and…
To determine protective immunity against a heterologous P. falciparum sporozoites re-challenge after previous CPS immunization and challenge.
This is a two part proof of efficacy study of KAF156 as a causal prophylactic agent in malaria. Results will be used to guide dose selection for further development of KAF156 in patients.
Objectives: • Primary objective (parasitological): To explore the longevity of immunity against P. falciparum sporozoite challenge that was induced in the EHMI-8 study. • Secondary objective (immunological): To dissect mechanisms of protection and…
Phase 1 • Primary objective: to determine the safety and tolerability, including the attenuation phenotype of a novel late-arresting GAP, named GA2 parasite, administered by sequentially increasing numbers of mosquito bites.• Secondary objective: to…
This study has been transitioned to CTIS with ID 2024-516488-99-00 check the CTIS register for the current data. Primary objectives: 1. To assess the effect of experimental immunization with GA2 sporozoites by mosquito bite with and without co-…
Primary safety objective: 1) To evaluate safety of R0.6C immunizations in healthy malaria-naïve volunteers in four dose-adjuvant combinations.Primary efficacy objective:1) To assess transmission reducing activity (TRA) to mosquitoes in the standard…
(protocol section 2) This phase 1 study aims to assess the safety and tolerability of monoclonal antibody TB31F administered intravenously or at escalating dose levels or subcutaneously in healthy, malaria naïve, adults. This study will also…